| Management target | Revenue FY27 |
|---|
| Margins | PAT turnaround at Ratna Lifescience from loss to ₹7.8 Cr. |
|---|---|
| Order book | IVD section received ₹50 Cr government order in 2021-22. |
| Demand visibility | Strong targeting of regulated and semi-regulated markets. |
| Management confidence | High |
Growth
Ratna Lifescience revenue grew from ₹0.02 Cr in FY23 to ₹35.30 Cr in FY26; PAT rose to ₹7.8 Cr.
Outlook
Targeting minimum ₹100 Cr export turnover for FY27; planned $20M FCCB allotment; new Hyderabad unit development.
Risks
Expansion into regulated markets like USA/Europe involves high regulatory compliance and competition from Chinese API imports.
Investor Presentation filed with BSE, BSE: 543828. Summary written with AI assistance from the document.
Sudarshan Pharma Industries Ltd: key numbers
- Share price
- ₹38.50
- Market cap
- ₹926.5 Cr
- Revenue (annual)
- ₹703.1 Cr
- Net profit (annual)
- ₹23.30 Cr
- P/E (TTM)
- 39.8×Sector 37.5×
- Promoter holding
- 58.93%+1.54% QoQ
- FII holding
- 19.88%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudarshan Pharma Industries Ltd
All →Sudarshan Pharma Industries Annual General Meeting
Sudarshan Pharma Industries Ltd held its 18th Annual General Meeting on September 22, 2026. The meeting covered the adoption of financial statements and director re-appointment.
Sudarshan Pharma Industries Acquisition
Sudarshan Pharma stated its proposed 9.50% stake acquisition of Med Therapy Biotechnology Inc. remains under due diligence. Promoter acquisitions of 1.50% each are also pending.
Sudarshan Pharma Industries Share Pledge
Sudarshan Pharma Industries Ltd announced the release of a pledge of 20,00,000 equity shares held by its promoter, Mr. Hemal Mehta. This disclosure complies with SEBI regulations.
Sudarshan Pharma Industries Acquisition
Sudarshan Pharma Industries will acquire a 9.50% stake in MedTherapy Biotechnology Inc. for cash. Its promoters will separately acquire an additional 3% combined stake.
- Execution
- 31st March 2027
Sudarshan Pharma Industries Q1 FY27 Results: Net Profit ₹5.6 Cr, Up 40.0% YoY
Sudarshan Pharma Industries Ltd reported revenue from operations of ₹174.4 Cr (+20.0% YoY) and net profit of ₹5.6 Cr (+40.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹5.6 Cr · +40.0% YoY
Sudarshan Pharma Industries Q4 FY26 Results: Net Profit ₹11.4 Cr, Up 54.1% YoY
Sudarshan Pharma Industries Ltd reported revenue from operations of ₹220.9 Cr (+36.7% YoY) and net profit of ₹11.4 Cr (+54.1% YoY) for Q4 FY26.
- Key figure
- Net profit ₹11.4 Cr · +54.1% YoY